LDLR and familial hyperaldosteronism: Considering the pharmacological mechanism of statins, which partly decrease the LDL-C levels by stimulating LDLR expression in the liver, it is expected that patients suffering from homozygous FH with null LDLR gene mutations would be refractive to such therapy [43].